As shown in healthy volunteers, as well as in those with active acromegaly, pasireotide suppresses insulin secretion, with smaller reductions in glucagon secretion, resulting in elevated blood glucose; this is, at least in part, mediated by dampening of the incretin response (glucagon-like peptide 1 [GLP-1] and gastric inhibitory polypeptide [GIP]) (15, 16). Here, GIP is linked to acromegaly.